The effectiveness results for monotherapy, zidovudine plus didanosine and zidovudine plus zalcitabine groups were:
Death or disease progression rates per 100 person years, 39.6, 34.3 and 36.2, (p=0.24);
Disease-free survival at 12 months, 71.9%, 74.8% and 74.7%;
Disease-free survival at 24 months, 44.7%, 50.2% and 48.8%;
Disease-free survival at 36 months, 27.6%, 35.7% and 31.3%;
Survival rates at 12 months, 90.5%, 89.2% and 90.9%;
Survival rates at 24 months, 65.4%, 67.5% and 67.7%;
Survival rates at 36 months, 41.6%, 49.4% and 46.2%;
Incidence of adverse events per 100 person years, 26.5, 32.9 and 32.6.